A Case Report Overwhelming Response to TNF-Alfa Inhibitor Infliximab “innovator” Vs. Adalimumab “Bio-similar” in a Previously Therapy Naive Adult. Indian J Case Reports 2022, 8 (3), 58-61. https://doi.org/10.32677/ijcr.v8i3.3317.